In addition, JAK inhibitors have been approved in multiple diseases including AD. Data generated to date support our ongoing clinical efforts including our ongoing Phase 2a trial of ATI-2138 in AD.” ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback